Korean J Lab Med.  2006 Feb;26(1):21-26. 10.3343/kjlm.2006.26.1.21.

Emergence of CTX-M-12 and A Novel CTX-M Type Extended-Spectrum beta-Lactamaseproducing Klebsiella pneumoniae

• Bae IK
• Jeong SH
• Lee K
• Yong D
• Lee J
• Hong SG
• Kim EC
• Park YJ
• Kang JO
• Uh Y
• Shin JH
• Lee WG
• Ahn JY
• Lee SH
• Woo GJ
• Kwak HS

• KMID: 2143192
• DOI: http://doi.org/10.3343/kjlm.2006.26.1.21

Abstract

BACKGROUND: The aims of this study were to survey the nation-wide susceptibilities of Klebsiella pneumoniae isolates against ceftazidime and cefotaxime and to determine the prevalence of class A extended-spectrum beta-lactamases (ESBLs).
METHODS
During the period of February to July 2004, K. pneumoniae isolates intermediate or resistant to ceftazidime and/or cefotaxime were collected from 12 hospitals in Korea. Antimicrobial susceptibilities were determined by the disk diffusion and the agar dilution methods and ESBL-production was by double-disk synergy test. Ceftazidime or cefotaxime-resistance determinants of the ESBLproducers were transfered to Escherichia coli J53 by transconjugation. Searches for class A ESBL genes were performed by PCR amplication.
RESULTS
Among 212 clinical K. pneumoniae isolates, 172 (81%) isolates showed positive results in double-disk synergy test; the most prevalent ESBL was SHV-12 (n=104). Genes encoding ESBLs including SHV-2 (n=6), SHV-2a (n=17), CTX-M-3 (n=18), CTX-M-9 (n=6), CTX-M-12 (n=1), CTX-M- 14 (n=27), CTX-M-15 (n=3), and a novel CTX-M-type beta-lactamases were also detected.
CONCLUSIONS
It is concluded that diversity of ESBLs in K. pneumoniae isolates are increasing in Korea. CTX-M-12 has never been reported in Asia, and a novel CTX-M-type ESBL has emerged.

Keyword

Klebsiella pneumoniae; Class A ESBL

MeSH Terms

Agar
Asia
beta-Lactamases
Cefotaxime
Ceftazidime
Diffusion
Escherichia coli
Klebsiella pneumoniae*
Klebsiella*
Korea
Pneumonia
Polymerase Chain Reaction
Prevalence
Agar
Cefotaxime
Ceftazidime
beta-Lactamases

Reference

References

1. Kim JM, Jeong SH, Lee SH, Kim JH, Kim BN, Kim JC. Prevalence and mechanism of third-generation cephalosporins-resistant Escherichia coli and Klebsiella pneumoniae stranis isolated from clinical specimen. Korean J Clin Microbiol. 2002; 5:6–14.

2. Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identification of CTXM-14 extended-spectrum β-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J Clin Microbiol. 2001; 39:3747–9.

3. Bae IK, Woo GJ, Jeong SH, Park KO, Cho BK, Kim DM, et al. Prevalence of CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Korea. Korean J Clin Microbiol. 2004; 7:48–54.

4. Hong YR, Yu H, Bae IK, Kwon SB, Jeong SH, Kim HJ, et al. Emergence of CTX-M-9 extended-spectrum β-lactamase-producing Enterobactr cloacae isolates. Korean J Clin Microbiol. 2005; 8:57–65.

5. Yong D, Shin JH, Kim S, Lim Y, Yum JH, Lee K, et al. High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. in Korea. Antimicrob Agents Chemother. 2003; 47:1749–51.

6. Jeong SH, Bae IK, Kwon SB, Lee K, Yong D, Woo GJ, et al. Investigation of a nosocomial outbreak of Acinetobacter baumannii producing PER-1 extended-spectrum beta-lactamase in an intensive care unit. J Hosp Infect. 2005; 59:242–8.

7. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P. Molecular and Biochemical Characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother. 1999; 43:573–81.

8. Kim JY, Park YJ, Kim SI, Kang MW, Lee SO, Lee KY. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum β-lactamase VEB-1 in a Korean university hospital. J Antimicrob Chemother. 2004; 54:1144–7.

9. Lee SH, Jeong SH. Nomenclature of GES-type extended-spectrum beta-lactamses. Antimicrob Agents Chemother. 2005; 49:2148–50.

10. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing, Tenth informational supplement, M100-S10 (M2). Wayne, Pa: National Committee for Clinical Laboratory Standards;2000.

11. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically 5th edition: approved standards. Wayne: National Committee for Clinical Laboratory Standards;2000. p. M7–A5.

12. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988; 10:867–78.

13. Jacoby JA, Han P. Detection of extended broad-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 1996; 34:908–11.

14. Kimura S, Ishiguro M, Ishii Y, Alba J, Yamaguchi K. Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis. Antimicrob Agents Chemother. 2004; 48:1454–60.

15. Sturenburg E, Kuhn A, Mack D, Laufs R. A novel extended-spectrum β-lactamase CTX-M-23 with a P167T substitution in the active-site omega loop associated with ceftazidime resistance. J Antimicrob Chemother. 2004; 54:406–9.

16. Kariuki S, Corkill JE, Revathi G, Musoke R, Hart CA. Molecular characterization of a novel plasmid-encoded cefotaximase (CTX-M-12) found in clinical Klebsiella pneumoniae isolates from Kenya. Antimicrob Agents Chemother. 2001; 45:2141–3.

17. Villegas MV, Correa A, Perez F, Zuluaga T, Radice M, Gutkind G, et al. CTX-M-12 β-lactamase in a Klebsiella pneumoniae clinical isolate in Colombia. Antimicrob Agents Chemother. 2004; 48:629–31.

18. Kang JH, Bae IK, Kwon SB, Jeong SH, Lee J, Lee WG, et al. Prevalence of Amber class A extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Korea. Korean J Clin Microbiol. 2005; 8:17–25.